Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease

被引:9
作者
Otgonsuren, Munkhzul [1 ]
Henry, Linda [1 ]
Hunt, Sharon [1 ]
Venkatesan, Chapy [2 ]
Mishra, Alita [2 ]
Younossi, Zobair M. [1 ,2 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA 22042 USA
[2] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA
关键词
Advanced liver disease; Medicare; Resource utilization; Mortality; Predictors; CHRONIC HEPATITIS-C; HEALTH-CARE COSTS; HEPATOCELLULAR-CARCINOMA; CIRRHOSIS; IMPACT; BENEFICIARIES; COMPLICATIONS; EPIDEMIOLOGY; MANAGEMENT; MORBIDITY;
D O I
10.1007/s10620-014-3318-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The prevalence of advanced liver disease and its complications may be on the rise within the Medicare population. The study aim was trend assessment for prevalence, mortality and resource utilization of patients with advanced liver disease. A retrospective, cross-sectional design was used to analyze a national sample of non-institutionalized Medicare in/outpatients from 2005 to 2009. Cases were ascertained by International Classification of Diseases, 9th Edition. Outcomes were overall mortality (within 1 year) and resource utilization [hospital length of stay (LOS/days) and institutional costs to Medicare]. Multivariate analyses were used to estimate the odds ratios for mortality predictors; linear regression was used for resource utilization predictors. A total of 21,913 beneficiaries with advanced liver disease were identified in the Medicare inpatient and outpatient administrative data sets from 2005 to 2009. Over 70 % of the beneficiaries with advanced liver disease died during study time period with 17 % dying while hospitalized. Predictors of mortality were: admission to the intensive care unit (ICU) and increasing Charlson Comorbidity Index. Predictors for increased LOS and cost were: ICU admission and having a thoracentesis procedure (both indicators of the levels of illness). Advanced liver disease and its related complication are increasing in the Medicare population and are associated with very high mortality. Further study is warranted to understand the drivers of the increased prevalence of advanced liver disease for earlier identification and treatment.
引用
收藏
页码:320 / 332
页数:13
相关论文
共 37 条
  • [11] Multiple interactive factors in hepatocarcinogenesis
    Ding, Jin
    Wang, Hongyang
    [J]. CANCER LETTERS, 2014, 346 (01) : 17 - 23
  • [12] Epidemiology of hepatocellular carcinoma in USA
    El-Serag, Hashem B.
    [J]. HEPATOLOGY RESEARCH, 2007, 37 : S88 - S94
  • [13] Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
    El-Serag, Hashem B.
    [J]. GASTROENTEROLOGY, 2012, 142 (06) : 1264 - +
  • [14] Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?
    Giannini, Edoardo G.
    Cucchetti, Alessandro
    Erroi, Virginia
    Garuti, Francesca
    Odaldi, Federica
    Trevisani, Franco
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (47) : 8808 - 8821
  • [15] EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver
    Gines, Pere
    Angeli, Paolo
    Lenz, Kurt
    Moller, Soren
    Moore, Kevin
    Moreau, Richard
    Merkel, Carlo
    Ring-Larsen, Helmer
    Bernardi, Mauro
    [J]. JOURNAL OF HEPATOLOGY, 2010, 53 (03) : 397 - 417
  • [16] Impact of Disease Severity on Healthcare Costs in Patients with Chronic Hepatitis C (CHC) Virus Infection
    Gordon, Stuart C.
    Pockros, Paul J.
    Terrault, Norah A.
    Hoop, Robert S.
    Buikema, Ami
    Nerenz, David
    Hamzeh, Fayez M.
    [J]. HEPATOLOGY, 2012, 56 (05) : 1651 - 1660
  • [17] Heidelbaugh JJ, 2006, AM FAM PHYSICIAN, V74, P767
  • [18] Heidelbaugh JJ, 2006, AM FAM PHYSICIAN, V74, P756
  • [19] Survival and re-admission of patients admitted with alcoholic liver disease to a West of Scotland hospital
    Heydtmann, M.
    McDonald, S. A.
    [J]. SCOTTISH MEDICAL JOURNAL, 2013, 58 (03) : 134 - 138
  • [20] A model to predict survival in patients with end-stage liver disease
    Kamath, PS
    Wiesner, RH
    Malinchoc, M
    Kremers, W
    Therneau, TM
    Kosberg, CL
    D'Amico, G
    Dickson, ER
    Kim, WR
    [J]. HEPATOLOGY, 2001, 33 (02) : 464 - 470